Amgen Trades Above Analyst Targets Amid Sjögren's Breakthrough

Amgen's experimental drug dazodalibep has shown promising results in treating moderate-to-severe systemic Sjögren's disease, a condition with no approved treatments. The Phase 3 data release comes after the company saw significant interest this year, with its stock price returning 25.21% year-to-date and 47.00% over the past 12 months.

The autoimmune breakthrough has led to Amgen trading above the average analyst target, while screens flag a sizeable intrinsic discount. This suggests that investors are paying a premium not backed by fundamentals, with some analysts suggesting the stock is 14% overvalued at $410.24 compared to a fair value of $359.98.

However, Amgen bears face real risk if autoimmune assets like dazodalibep gain traction or if obesity pipeline execution exceeds current cautious expectations. The company's cash flow model estimates future cash flow value at $669.25, which is 38.7% above the current price and frames AMGN as undervalued.